The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities.

ABSTRACT: Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood. The genomic landscape of pediatric ALL has been extensively characterized, allowing for the identification of distinct molecular subtypes of this disease. This in turn has facilitated improvements in risk stratification and tailoring of therapy, resulting in dramatic improvements in survival rates over the past several decades. However, despite these improvements, outcomes remain dismal for the ten percent of patients who continue to fail therapy and relapse. Although the genetic landscape of pediatric ALL is well-understood, increasing evidence suggests that genetic alterations alone are insufficient to promote leukemogenesis and the acquisition of chemoresistance that leads to disease relapse. Instead, coopera

SUBMITTER: Meyer LK 

PROVIDER: S-EPMC8992636 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature